R&D Evolving with the patient: Optimising CAGT post-trial long-t... The tremendous growth in cell and gene therapy is no surprise to the pharma industry.
News Veraxa says delayed US listing is back on track Swiss biotech Veraxa's listing on the Nasdaq, delayed by the record 43-day US government shutdown, should now complete in the first quarter of 2026.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
